6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe
Surmodics, Inc. (NASDAQ:SRDX) announced the presentation of 6-month data from the SWING Trial, evaluating the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon. This first-in-human study will be presented by Professor Ramon Varcoe on October 11 at the Amputation Prevention Symposium in Switzerland. The Sundance Balloon aims to offer a new treatment for patients with Critical lower limb ischemia, potentially improving quality of life and reducing surgical intervention needs. The device is currently for investigational use only and not for sale.
- Presentation of promising 6-month data from the SWING Trial.
- Potential to improve treatment for Critical lower limb ischemia.
- Aiming to reduce the need for major bypass surgeries.
- The Sundance Drug-Coated Balloon is not yet available for sale.
- Currently only for investigational use, limiting revenue potential.
35-subject trial evaluating safety, performance of Surmodics’ Sundance™ Sirolimus Drug-Coated Balloon
TITLE: Surmodics SWING BTK Trial
DATE:
TIME: 1:10 –
VENUE: Palazzo dei Congressi, Main Hall
The Sundance Sirolimus Drug-Coated Balloon utilizes a next-generation coating technology consisting of microcrystalline sirolimus and a proprietary excipient to maximize drug transfer, enhancing sirolimus delivery and sustaining therapeutic levels in the artery. Sirolimus, a potent anti-inflammatory and anti-proliferative compound, has been used successfully in coronary drug-eluting stents. The delivery of sirolimus to the vessel wall during mechanical dilatation provides an ancillary action of inhibiting the proliferation of cells, with the intended purpose of reducing restenosis. The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.
“The Sundance Sirolimus Drug-Coated Balloon represents a significant advancement in the treatment of patients with Critical lower limb ischemia and infrapopliteal arterial disease, providing a revascularization option that may lead to an improved quality of life, the reduced need for major bypass surgical intervention, and a decrease in the risk of amputation,” said Varcoe. “I am excited to present the 6-month SWING data to an audience of my peers at AMP Europe.”
About
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding the Sundance™ Sirolimus DCB, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including (1) our ability to successfully develop, obtain regulatory approval for, and commercialize our proprietary products; and (2) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20221007005073/en/
ir@surmodics.com
Source:
FAQ
What is the significance of the SWING Trial for Surmodics (SRDX)?
When will Surmodics present data from the SWING Trial?
What is the current status of the Sundance Sirolimus Drug-Coated Balloon?
Who is Professor Ramon Varcoe in relation to Surmodics (SRDX)?